By admin 
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month, sending shockwaves through the global pharmaceutical landscape and casting a long shadow over the future of lipid-lowering therapies. While the industry has long been accustomed to the high-risk, high-reward nature of drug development, the collapse of these specific programs—particularly the highly anticipated pelacarsen—represents more than just a balance sheet loss; it signals a potential "chilling effect" that could freeze investment in cardiovascular research for years to come. Just before Labor Day, Novartis reported that its cardiac therapy, pelacarsen, failed in a widely watched, seven-year clinical trial, a blow that has forced researchers and investors alike to re-examine the fundamental biological hypotheses underlying the next generation of heart disease treatments.
The drug, developed in collaboration with Ionis Pharmaceuticals, was designed to reduce the rates of heart attack or stroke by lowering lipoprotein(a), or Lp(a). This type of lipid is a complex particle in the blood that, at elevated concentrations, significantly increases the likelihood of severe heart problems, including atherosclerosis, aortic stenosis, and myocardial infarction. Unlike LDL cholesterol, which can often be managed through diet, exercise, and statins, Lp(a) levels are almost entirely determined by a person’s genetics. Because lifestyle modifications have little to no impact on these levels, an estimated 20% of the global population—roughly one in five people—carries a genetic predisposition to high Lp(a), leaving them at a heightened risk for cardiovascular events regardless of their fitness or health habits.
Novartis’s drug was the first major attempt at a new type of cardiovascular treatment targeting this specific genetic driver. The industry had been watching the Lp(a)HORIZON trial with bated breath, as it was the first Phase 3 study to test whether aggressively lowering this specific protein would actually translate into fewer deaths and hospitalizations. Multiple other drug companies are also pursuing this "Lp(a) hypothesis," investing billions of dollars in their own medications, including Amgen, Eli Lilly, and Silence Therapeutics. The failure of pelacarsen to meet its primary endpoint of reducing major adverse cardiovascular events (MACE) suggests that the relationship between lowering the biomarker and improving patient outcomes is far more complex than previously understood.
To understand the weight of this failure, one must look at the history of cardiovascular medicine. For decades, the "Gold Standard" has been the reduction of LDL cholesterol. The success of statins and, more recently, PCSK9 inhibitors, solidified the idea that if you lower the "bad" cholesterol, you lower the risk of heart disease. However, as the medical community began to realize that many patients continued to have heart attacks even with low LDL levels, the search for "residual risk" factors intensified. Lp(a) emerged as the primary suspect. Pelacarsen utilized antisense oligonucleotide (ASO) technology to essentially "silence" the gene responsible for producing the protein component of Lp(a) in the liver. By blocking the messenger RNA, the drug could theoretically slash Lp(a) levels by 80% or more.
The clinical failure of pelacarsen, despite its proven ability to drastically lower the Lp(a) biomarker, evokes memories of the ill-fated CETP inhibitors of the early 2010s. Drugs like Pfizer’s torcetrapib and Eli Lilly’s evacetrapib were designed to raise "good" HDL cholesterol to record levels. They succeeded in changing the blood chemistry, but the patients taking them died at higher rates or showed no benefit. The Novartis failure suggests that Lp(a) may be a marker of risk rather than a direct cause that can be reversed mid-life, or perhaps that the threshold for reduction must be even more extreme to yield a clinical benefit.
Simultaneously, Novo Nordisk, the Danish pharmaceutical giant currently riding a wave of unprecedented success with its GLP-1 agonists like Wegovy and Ozempic, also faced a significant setback in its cardiovascular pipeline. While the company has successfully proven that its weight-loss drugs provide secondary heart benefits, its dedicated cardiovascular programs have hit roadblocks. These twin failures from two of the world’s most well-capitalized and experienced pharmaceutical companies suggest that the "low-hanging fruit" in heart disease has been picked. What remains are the most difficult, genetically driven pathologies that require decades of study and billions in capital.
The "chilling effect" mentioned by industry analysts refers to the potential retreat of venture capital and big pharma R&D budgets from the cardiovascular space. In recent years, oncology and rare diseases have dominated the biotech sector because they often allow for smaller clinical trials and faster paths to regulatory approval. In contrast, cardiovascular trials like the one for pelacarsen are massive undertakings. The Lp(a)HORIZON trial involved over 8,000 patients and lasted seven years. When a project of that magnitude fails, it doesn’t just result in a write-down; it discourages boards of directors from greenlighting similar long-term, high-cost endeavors.
For competitors like Amgen and Eli Lilly, the Novartis news is a double-edged sword. On one hand, it removes a massive first-mover advantage from Novartis. On the other hand, it casts doubt on their own pipelines. Amgen’s olpasiran and Lilly’s lepodisiran use a slightly different technology known as small interfering RNA (siRNA). While siRNA tends to be more potent and requires less frequent dosing than the ASO technology used by Novartis, the underlying biological target remains the same. If the problem with the Novartis trial was the target (Lp(a)) rather than the delivery mechanism, then the entire multi-billion-dollar class of drugs may be in jeopardy.
The implications for public health are equally sobering. Heart disease remains the leading cause of death globally, accounting for nearly 20 million deaths per year. The medical community had hoped that Lp(a) inhibitors would be the "next statin," a blockbuster category of drugs that could save millions of lives by addressing the genetic component of heart disease that has remained untreatable for a century. With the failure of pelacarsen, that hope has been deferred, if not extinguished. Cardiologists are now left to wonder if the 20% of the population with high Lp(a) will ever have a targeted therapy, or if they must continue to rely on managing other risk factors with increasing intensity.
Furthermore, the Novartis setback highlights the growing tension between surrogate endpoints and clinical outcomes. Regulatory agencies like the FDA have occasionally granted accelerated approval to drugs that successfully change a biomarker (like lowering a specific protein), assuming that the clinical benefit will follow. However, the pelacarsen failure reinforces the necessity of "hard outcome" trials. It proves that a drug can be a "scientific success" in terms of its mechanism of action while being a "clinical failure" in terms of saving lives. This realization may lead regulators to demand even more rigorous, longer-term data before approving any new cardiovascular medications, further increasing the cost and time required for innovation.
The financial markets have already begun to price in this increased risk. Biotech startups focusing on cardiovascular health have seen a tightening of available capital as investors pivot toward more "predictable" fields like immunology or metabolic health (GLP-1s). For the scientists and executives at companies like Silence Therapeutics, which is also developing an Lp(a) drug, the challenge now is to convince the market that their specific approach—perhaps by achieving even deeper or earlier suppression of the lipid—will succeed where Novartis failed.
As the industry digests the data from the pelacarsen trial, the focus will shift to the specific patient subgroups. Analysts are looking to see if the drug worked better in certain ethnicities or in patients with pre-existing advanced heart disease. If a "signal" of efficacy can be found in the wreckage of the trial, Novartis might attempt to salvage the program for a more niche population. However, the "blockbuster" dream of a universal treatment for the one-in-five people with high Lp(a) has certainly taken a devastating hit.
In conclusion, the back-to-back failures of Novartis and Novo Nordisk serve as a stark reminder of the inherent volatility in drug development. Even with the most advanced genetic tools and billions of dollars in backing, the human heart remains a complex and often unpredictable organ to treat. The "chilling effect" of these setbacks will likely be felt in the coming years through more conservative R&D spending and a higher bar for entry for new cardiovascular startups. For now, the millions of patients with elevated Lp(a) must wait, as the scientific community goes back to the drawing board to figure out why a drug that did exactly what it was designed to do—lower a dangerous lipid—still wasn’t enough to stop the progression of heart disease.
